

Reviewer #1:

Scientific Quality: Grade C (Good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Minor revision


Specific Comments to Authors:

1. The manuscript investigated the effect of ulinastatin combined with dexmedetomidine on POCD and emergence agitation in elderly patients undergoing total hip arthroplasty. However, However, it is confusing that several unilateral knee arthroplasty have appeared in the Methods and Results section of the text. Please make sure you are writing incorrectly?

Response: Thank you very much for your interest in our manuscript entitled *Effects of ulinastatin combined with dexmedetomidine on postoperative cognitive dysfunction and emergence agitation in elderly patients undergoing total hip arthroplasty*. To address the comments and concerns you have raised, we have included a point-by-point response to each comment. Within the revised manuscript, changes to the text in response to the comments are marked in the blue font. We really apologized for this careless mistake about the wrong statement. This is a careless mistake that we inserted the wrong words. We have corrected all the mistakes in the revised manuscript.

2. Outcome measures and statistical analysis: 576 elderly patients who underwent were selected. Among them, 129 patients were included in the Dex group. One hundred fifty patients included in the ulinastatin group. One hundred eighteen patients in the combined group. 576 patients did not match $129 + 150 + 118$ patients of the three groups described later. Through the description of the Results section, I understand that 576 patients were all screened and included those who met and did not meet the inclusion requirements, but needed to be described clearly.

Response: Thank you for pointing out this issue. We supplemented the Flow diagram describing the collection of patients in the Result 3.1 section in the revised manuscript. The added Figure is as follows:



3. Regarding the combination group of dexmedetomidine and ulinastatin, some are expressed as "combined group" and some use "Dex+ Ulinastatin group". It is suggested to

describe it as uniformly as possible.

Response: Thanks for your kindly reminding. In the revised manuscript, we unified them as the "Dex+ Ulinastatin group" according to your suggestion.

Reviewer #2:

Scientific Quality: Grade C (Good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Minor revision


Specific Comments to Authors:

1. The manuscript investigated the effect of ulinastatin combined with dexmedetomidine on POCD and emergence agitation in elderly patients undergoing total hip arthroplasty. However, However, it is confusing that several unilateral knee arthroplasty have appeared in the Methods and Results section of the text. Please make sure you are writing incorrectly?

Response: Thanks for your kindly reminding. We really apologized for this careless mistake about the wrong statement. This is a careless mistake that we inserted the wrong words. We have corrected all the mistakes in the revised manuscript.

2. Outcome measures and statistical analysis: 576 elderly patients who underwent were selected. Among them, 129 patients were included in the Dex group. One hundred fifty patients included in the ulinastatin group. One hundred eighteen patients in the combined group. 576 patients did not match 129 + 150 + 118 patients of the three groups described later. Through the description of the Results section, I understand that 576 patients were all screened and included those who met and did not meet the inclusion requirements, but needed to be described clearly.

Response: Thank you for pointing out this issue. We supplemented the Flow diagram describing the collection of patients in the Result 3.1 section in the revised manuscript. The added Figure is as follows:



3. Regarding the combination group of dexmedetomidine and ulinastatin, some are expressed as "combined group" and some use "Dex+ Ulinastatin group". It is suggested to describe it as uniformly as possible.

Response: Thanks for your kindly reminding. In the revised manuscript, we unified them as the "Dex+ Ulinatastatin group" according to your suggestion.